Marks Tyler, Wingerter Scott, Franklin Laura, Woodall James, Tucci Michelle, Russell George, Patel Ramesh, Benghuzzi Hamed
School of Medicine, School of Graduate Studies in Health Sciences, Department of Orthopaedic Surgery and Rehabilitation, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Biomed Sci Instrum. 2007;43:194-9.
Demineralized bone matrix (DBM) has been shown to possess osteoinductive capability and one of the specific bone morphogenetic proteins (BMPs) found within DBM that has been attributed with this osteoinductive ability is BMP-7, also known as osteogenic protein-1 (OP-1). The specific aims of this study were (1) to compare the treatment of segmental bone defects with OP-l and DBM in a rat femur model and (2) to determine the effects of the two treatments given at high and low doses via sustained release drug delivery. Animals in Group 1 acted as the control and Group 2 had a created segmental defect with plating and placement of a calcined tricalcium phosphate lysine (TCPL) capsule containing antibiotic (sham). Group 3 and 4 animals had a created segmental defect and received a TCPL carrier containing antibiotic along with DBM or OP-1, respectively. After 4 weeks post-implantation, animals were sacrificed before the retrieval of the bone. The femora were analyzed radiographically and histologically for bone growth. Analysis of the gross specimens showed considerable bone regeneration at low and high doses for both DBM and OP-1 when compared to the shams. At low levels bone regeneration between DBM and OP-1 was very similar. However, at high doses, OP-1 was shown to cause bone overgrowth with a greater curvature and an increased thickness of the distal and proximal ends of the femur. The stained slides showed the defects treated with DBM and OP-1 to be bridged with lamellar and woven bone that was continuous with the original bone. Histologically, the experimental femora demonstrated natural remodeling processes with new osteons and angiogenesis.
脱矿骨基质（DBM）已被证明具有骨诱导能力，在DBM中发现的一种具有这种骨诱导能力的特定骨形态发生蛋白（BMP）是BMP - 7，也称为成骨蛋白 - 1（OP - 1）。本研究的具体目的是：（1）在大鼠股骨模型中比较用OP - 1和DBM治疗节段性骨缺损的效果；（2）确定通过缓释药物递送给予高剂量和低剂量的这两种治疗方法的效果。第1组动物作为对照，第2组制造节段性缺损并进行钢板固定，植入含抗生素的煅烧磷酸三钙赖氨酸（TCPL）胶囊（假手术）。第3组和第4组动物制造节段性缺损，并分别接受含抗生素的TCPL载体以及DBM或OP - 1。植入后4周，在取出骨头之前处死动物。对股骨进行放射学和组织学分析以评估骨生长情况。大体标本分析显示，与假手术组相比，DBM和OP - 1在高剂量和低剂量时均有相当程度的骨再生。在低剂量时，DBM和OP - 1之间的骨再生非常相似。然而，在高剂量时，OP - 1显示会导致骨过度生长，股骨远端和近端的曲率更大且厚度增加。染色切片显示，用DBM和OP - 1治疗的缺损处被与原始骨连续的板层骨和编织骨桥接。组织学上，实验性股骨表现出具有新骨单位和血管生成的自然重塑过程。
